1.
Cai Y, Hirata A, Nakayama S, et al. CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. PLoS One. 2015;10(3):e0120647. doi:10.1371/journal.pone.0120647.
1.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. doi:10.1038/nature11404.
1.
Chun E, Lavoie S, Michaud M, et al. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function. Cell Rep. 2015;12(2):244-57. doi:10.1016/j.celrep.2015.06.024.
1.
Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107-20. doi:10.1016/j.cell.2012.08.029.
1.
Stachler MD, Taylor-Weiner A, Peng S, et al. Paired exome analysis of Barrett’s esophagus and adenocarcinoma. Nat Genet. 2015;47(9):1047-55. doi:10.1038/ng.3343.
1.
Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478-86. doi:10.1038/ng.2591.
1.
Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305. doi:10.1038/nm.4045.
1.
Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153(3):666-77. doi:10.1016/j.cell.2013.03.021.
1.
Gannon HS, Kaplan N, Tsherniak A, et al. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2016;14(2):207-15. doi:10.1158/1541-7786.MCR-15-0321.
1.
Watanabe H, Meyerson M. Hopping between differentiation states in lung adenocarcinoma. Cancer Cell. 2013;23(6):707-9. doi:10.1016/j.ccr.2013.05.013.